✦ LIBER ✦

CV1 A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION

✍ Scribed by AG Hartzema; AG Winterstein; S Kwon

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV23: A COST-BENEFIT MODEL FOR PERINDOP

✍ AG Hartzema; AG Winterstein; SY Kwon 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

A Benefit-Risk Assessment of Agents Used

✍ Dr Ronald S. MacWalter, Colin P. Shirley 📂 Article 📅 2002 🏛 Springer International Publishing AG 🌐 English ⚖ 255 KB

Cost-effectiveness of apixaban vs warfar

✍ Kamel, H.; Easton, J. D.; Johnston, S. C.; Kim, A. S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 578 KB

PO03-MO-08 The cost burden for secondary

✍ C.H. Kim; H.Y. Rhee 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Novel Anticoagulants for Stroke Preventi

✍ Limone, Brendan L.; Baker, William L.; Kluger, Jeffrey; Coleman, Craig I.; Herna 📂 Article 📅 2013 🏛 Public Library of Science 🌐 English ⚖ 336 KB

P.8.a.003 Clinical and cost-effectivenes

✍ J. Mar; J. Vivancos; J. Rejas; A. Arrospide; J. Caro 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 103 KB